Evidence map›Paper›PMID 42626036›Full record

ArticleJCEM case reports2026

Lipoprotein X: artifactual lipid derangement in type 3c diabetes with obstructive liver disease.

Deirdre Green, Anusha Prem Kumar, Brendan Byrne, Eileen Byrne, Graham R Lee, Paula M O'Shea

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Deirdre GreenDept. of Endocrinology, Mater Misericordiae University Hospital, Dublin 7, D07 R2WY, Ireland.
Anusha Prem KumarDept. of Endocrinology, Mater Misericordiae University Hospital, Dublin 7, D07 R2WY, Ireland.ORCID https://orcid.org/0000-0002-3813-3234
Brendan ByrneDept. of Clinical Chemistry & Diagnostic Endocrinology, Mater Misericordiae University Hospital, Dublin 7, D07 R2WY, Ireland.
Eileen ByrneDept. of Clinical Chemistry & Diagnostic Endocrinology, Mater Misericordiae University Hospital, Dublin 7, D07 R2WY, Ireland.
Graham R LeeUCD School of Medicine, University College Dublin, Dublin 4, D04 V1W8, Ireland.
Paula M O'SheaUCD School of Medicine, University College Dublin, Dublin 4, D04 V1W8, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipoprotein X is an abnormal lipoprotein formed in cholestatic liver disease that causes artifactual elevation of calculated and measured direct low-density lipoprotein cholesterol (LDL-C). A 40-year-old man with chronic pancreatitis presented with hyperglycemic hyperosmolar state secondary to type 3c diabetes. He was jaundiced, with total bilirubin of 9.4 mg/dL (SI: 161 µmol/L) (reference range, 0.3-1.4 mg/dL [SI: 5-24 µmol/L]). Abdominal computed tomography showed severe common bile duct stricturing causing obstructive cholestasis. Laboratory results revealed a physiologically implausible lipid profile: total cholesterol (TC) of 1531 mg/dL (SI: 39.6 mmol/L) (desirable concentration, <200 mg/dL [SI: <5.2 mmol/L]) and direct LDL-C of 1636 mg/dL (SI: 42.3 mmol/L) (desirable concentration, <100 mg/dL [SI: <2.6 mmol/L]). Low-density lipoprotein cholesterol exceeding TC indicated analytical interference. Apolipoprotein B (ApoB) was elevated: 278 mg/dL (SI: 2.78 g/L) (reference range, 66-144 mg/dL [SI: 0.66-1.44 g/L]). The TC:ApoB ratio was 6.9 mmol/g (reference range, 3.8-6.3 mmol/g), supporting coexistent ApoB-negative lipoprotein. Liver and lipid parameters improved post-biliary stenting. ApoB normalized at 6 weeks, supporting a transient, insulin-deficiency-related ApoB-containing lipoprotein excess. Clinicians should suspect lipoprotein X when LDL-C exceeds TC in the setting of cholestasis; if ApoB is also elevated, transient ApoB-mediated dyslipidemia may coexist. Management centers on correcting underlying biliary and metabolic pathology.

Indexed as

cholestasislipidologylipoprotein

Identifiers

PMID42626036
PMCPMC13490867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.